tirzepatide weight loss clinical trials reduction with different doses of in Surmount 1 Tirzepatide's Surmount-4 Trial Reveals Groundbreaking

doi:10.1016/j.surg.2012.02.004

10.1080/15548627.2017.1390636 Autophagy 191 LiuS.PerezP.SunX.ChenK.FatirkhoraniR.MammadovaJ.et al (2024)

Packer noted that gastrointestinal reports, such as diarrhea, nausea, or constipation, led 4% discontinuation in the tirzepatide arm

The analyses of a trial called Select, whose results showed last year that Wegovy significantly reduced heart risk in addition to helping with weight loss also suggest that the drug may protect the heart in ways beyond weight loss alone, researchers said, raising new questions about how the wildly popular medicines in this drug class should be used and covered by insurers